Literature DB >> 18344861

Thromboembolic disease after combined anterior/posterior reconstruction for adult spinal deformity: a prospective cohort study using magnetic resonance venography.

Dana P Piasecki1, Ashley R Poynton, Douglas N Mintz, Jeffrey S Roh, Margaret G E Peterson, Bernard A Rawlins, Gina Charles, Oheneba Boachie-Adjei.   

Abstract

STUDY
DESIGN: Thromboembolic disease (TED) after anterior/posterior spinal reconstructions was prospectively evaluated in 66 consecutive patients.
OBJECTIVE: Determine the incidence of TED after anterior/posterior spinal reconstruction. SUMMARY OF BACKGROUND DATA: Few studies have examined the rate of TED after potentially high-risk combined anterior/posterior reconstructions. Magnetic resonance venography (MRV) is more effective at detecting pelvic deep venous thrombosis (DVT) than conventional screening, but has not been used in these patients.
METHODS: We undertook a prospective cohort study of 66 consecutive adult patients (mean, 52.7 +/- 9.6 years) undergoing combined anterior/posterior spinal reconstructions for spinal deformity. All patients received only mechanical DVT prophylaxis. After surgery, MRV and bilateral lower extremity Doppler ultrasounds were obtained to screen for DVT, and contrast-enhanced spiral computed tomography scans were obtained for clinical suspicion of pulmonary embolism (PE).
RESULTS: The total incidence of postoperative TED was 13.6% (9 patients). The overall rate of DVT was 9.1% (6 patients), one-third occurring in the pelvis. PE developed in 7.6% (5 patients). In 2 patients, PE developed less than 48 hours after positive dopplers. In 3 patients, PE developed despite negative screening studies. Right-sided thoracoabdominal approaches were associated with an increased risk of developing DVT (P = 0.03, Odds Ratio 9.8), PE (P = 0.01, Odds Ratio 20), and TED (P = 0.004, Odds Ratio 12).
CONCLUSION: We report a high rate of TED after extensive anterior/posterior spinal reconstructions, for which a right-sided thoracoabdominal approach is an independent risk factor and screening ineffective at preventing PE. These patients should be considered at high risk for postoperative TED.

Entities:  

Mesh:

Year:  2008        PMID: 18344861     DOI: 10.1097/BRS.0b013e318166dfa3

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  6 in total

1.  Incidence of venous thromboembolic complications in instrumental spinal surgeries with preoperative chemoprophylaxis.

Authors:  Saeed Hamidi; Mahdieh Riazi
Journal:  J Korean Neurosurg Soc       Date:  2015-02-26

2.  Perioperative Anticoagulation Management in Spine Surgery: Initial Findings From the AO Spine Anticoagulation Global Survey.

Authors:  Philip Louie; Garrett Harada; James Harrop; Thomas Mroz; Khalid Al-Saleh; Giovanni Barbanti Brodano; Jens Chapman; Michael Fehlings; Serena Hu; Yoshiharu Kawaguchi; Michael Mayer; Venugopal Menon; Jong-Beom Park; Sheeraz Qureshi; Shanmuganathan Rajasekaran; Marcelo Valacco; Luiz Vialle; Jeffrey C Wang; Karsten Wiechert; K Daniel Riew; Dino Samartzis
Journal:  Global Spine J       Date:  2020-04-17

3.  The Rate of Venous Thromboembolism Before and After Spine Surgery as Determined with Indirect Multidetector CT.

Authors:  Hirokazu Inoue; Hideaki Watanabe; Hitoshi Okami; Atsushi Kimura; Katsushi Takeshita
Journal:  JB JS Open Access       Date:  2018-08-15

4.  D-dimer predicts pulmonary embolism after low-risk spine surgery.

Authors:  Hirokazu Inoue; Hideaki Watanabe; Hitoshi Okami; Atsushi Kimura; Atsushi Seichi; Katsushi Takeshita
Journal:  Spine Surg Relat Res       Date:  2018-02-28

5.  Pulmonary embolism after a single-stage, combined anterior and posterior approach lumbar surgery.

Authors: 
Journal:  Pak J Med Sci       Date:  2013-11       Impact factor: 1.088

6.  Thromboprophylaxis in elective spinal surgery: A protocol for systematic review.

Authors:  María J Colomina; Joan Bagó; Javier Pérez-Bracchiglione; Maria Betina Nishishinya Aquino; Karla R Salas; Carolina Requeijo; Gerard Urrútia
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.